Unknown

Dataset Information

0

Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity.


ABSTRACT: Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of ∼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer's Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company's 'lightspeed' paradigm.

SUBMITTER: Fernando K 

PROVIDER: S-EPMC8719639 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8189733 | biostudies-literature
| S-EPMC8076232 | biostudies-literature
| S-EPMC9091239 | biostudies-literature
| S-EPMC6746521 | biostudies-literature
| S-EPMC5013773 | biostudies-literature
| S-EPMC6717284 | biostudies-literature
| S-EPMC9477509 | biostudies-literature
| S-EPMC3271934 | biostudies-literature
| S-EPMC4670843 | biostudies-other
| S-EPMC5495753 | biostudies-literature